Active, Not Recruiting
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156
- Conditions
- Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, +6 more
- Locations
-
- University of California-San Diego/Moores UCSD Cancer Center La Jolla, California, United States
- UCLA David Geffen School of Medicine Los Angeles, California, United States
- Smilow Cancer Center at YNHH New Haven, Connecticut, United States
- BRCR Medical Center Inc Plantation, Florida, United States